Danish researchers report that low-level skipping of CD19 exon 2—detectable in pre-treatment RNA-seq—correlates with relapse after anti-CD19 CAR-T therapy. The study positions an accessible pre-treatment splicing readout as a candidate biomarker for stratifying relapse risk and informs future assay development for companion diagnostics in CAR-T workflows.